The Use of Vital and Morbidity Statistics for the Detection of Adverse Drug Reactions and for Monitoring of Drug Safety

1982 ◽  
Vol 22 (11) ◽  
pp. 499-504 ◽  
Author(s):  
PAUL D. STOLLEY
Keyword(s):  
Adverse Drug Reactions ◽  
Drug Safety ◽  
Drug Reactions

METHODOLOGIES FOR ASSESSING DRUG SAFETY, EFFECTIVENESS AND ADVERSE DRUG REACTIONS

2018 ◽  
Vol 20 (3) ◽  
pp. 112-117
Author(s):  
O.I. Slyusar ◽  
◽  
A.B. Kachalov ◽  
M.V. Ryzhkova ◽  
I.В. Slyusar ◽  
...  
Keyword(s):  
Adverse Drug Reactions ◽  
Drug Safety ◽  
Drug Reactions ◽  
Safety Effectiveness

scholarly journals Operation Save the World from Adverse Drug Reactions: findings from a drug safety surveillance programme in Nigeria

2019 ◽  
Vol 7 ◽  
pp. S46 ◽  
Author(s):  
Yohanna Kambai Avong ◽  
Bolajoko Jatau ◽  
Gbenga Ayodele Kayode ◽  
Blessing Ukpabi ◽  
Eunice Bosede Avong ◽  
...  
Keyword(s):  
Adverse Drug Reactions ◽  
Drug Safety ◽  
Drug Reactions ◽  
Surveillance Programme ◽  
Safety Surveillance ◽  
Drug Safety Surveillance ◽  
The World

Sex Differences in Adverse Drug Reactions Using the Korea Institute of Drug Safety and Risk Management Database

Yakhak Hoeji ◽  
2020 ◽  
Vol 64 (1) ◽  
pp. 79-86
Author(s):  
Ha Rim Yeon ◽  
Sang Oh Kang ◽  
Kyung Hyun Min ◽  
Yunjeong Choi ◽  
Boyoung Hwang ◽  
...  
Keyword(s):  
Risk Management ◽  
Sex Differences ◽  
Adverse Drug Reactions ◽  
Drug Safety ◽  
Drug Reactions ◽  
Management Database

Adverse Drug Reactions, Iatrogenic Diseases, Drug Safety, and Pharmacovigilance: Importance and Interest for Patients and Their Physicians

2021 ◽  
pp. 1-6
Author(s):  
Jean-Louis Montastruc ◽  
Haleh Bagheri ◽  
Genevieve Durrieu ◽  
Isabelle Lacroix ◽  
François Montastruc
Keyword(s):  
Adverse Drug Reactions ◽  
Drug Safety ◽  
Drug Reactions

scholarly journals Public engagement and the role of the media in post-marketing drug safety: the case of Eltroxin® (levothyroxine) in New Zealand

2020 ◽  
Author(s):  
Kevin Dew ◽  
J Gardner ◽  
EH Morrato ◽  
P Norris ◽  
K Chamberlain ◽  
...  
Keyword(s):  
New Zealand ◽  
Adverse Drug Reactions ◽  
Drug Safety ◽  
Public Engagement ◽  
Sharp Increase ◽  
Drug Reactions ◽  
Media Attention ◽  
Adr Reporting ◽  
The Media

© 2017, © 2017 Informa UK Limited, trading as Taylor & Francis Group. The potential for harms from adverse drug reactions (ADR) constitutes a critical patient safety and public health challenge, especially with increased medication usage as populations age. The research reported here explores explanations for a sudden increase in ADR reporting in New Zealand after a new formulation of a medication to treat hypothyroidism, Eltroxin® (levothyroxine), was phased in. The formulation was adjudged to be bioequivalent to the old formulation, yet following its introduction, a sharp increase in the reporting of adverse reactions to this drug occurred. The paper analyses public engagement and the role of print media coverage, press releases and minutes of meetings of relevant agencies in order to describe the unfolding of this health controversy. Early interpretations of the sharp increase in reporting of reactions explained it as an outcome of a combination of factors, including a mistrust of state drug subsidising agencies and media attention that provoked anxiety in this vulnerable population. This paper offers an alternative explanation arguing that, as adverse drug reactions are known to be significantly underreported, the Eltroxin® ‘health scare’ illustrates enhanced pharmacovigilance triggered by the interaction between patients and the media. The Eltroxin® controversy is an illustrative case example of the amplification of ADR reporting by patients following increased media attention in the context of a low consumer reporting environment. The case of Eltroxin® indicates that drug safety can be enhanced by actively using media sources and by encouraging patient engagement and reporting of ADRs.

scholarly journals Public engagement and the role of the media in post-marketing drug safety: the case of Eltroxin® (levothyroxine) in New Zealand

2020 ◽  
Author(s):  
Kevin Dew ◽  
J Gardner ◽  
EH Morrato ◽  
P Norris ◽  
K Chamberlain ◽  
...  
Keyword(s):  
New Zealand ◽  
Adverse Drug Reactions ◽  
Drug Safety ◽  
Public Engagement ◽  
Sharp Increase ◽  
Drug Reactions ◽  
Media Attention ◽  
Adr Reporting ◽  
The Media

© 2017, © 2017 Informa UK Limited, trading as Taylor & Francis Group. The potential for harms from adverse drug reactions (ADR) constitutes a critical patient safety and public health challenge, especially with increased medication usage as populations age. The research reported here explores explanations for a sudden increase in ADR reporting in New Zealand after a new formulation of a medication to treat hypothyroidism, Eltroxin® (levothyroxine), was phased in. The formulation was adjudged to be bioequivalent to the old formulation, yet following its introduction, a sharp increase in the reporting of adverse reactions to this drug occurred. The paper analyses public engagement and the role of print media coverage, press releases and minutes of meetings of relevant agencies in order to describe the unfolding of this health controversy. Early interpretations of the sharp increase in reporting of reactions explained it as an outcome of a combination of factors, including a mistrust of state drug subsidising agencies and media attention that provoked anxiety in this vulnerable population. This paper offers an alternative explanation arguing that, as adverse drug reactions are known to be significantly underreported, the Eltroxin® ‘health scare’ illustrates enhanced pharmacovigilance triggered by the interaction between patients and the media. The Eltroxin® controversy is an illustrative case example of the amplification of ADR reporting by patients following increased media attention in the context of a low consumer reporting environment. The case of Eltroxin® indicates that drug safety can be enhanced by actively using media sources and by encouraging patient engagement and reporting of ADRs.

Sign in / Sign up

Export Citation Format

Share Document